post split if you do today. If open next day it will jump +3 so equal to $21.
Big line when it crosses $100 investors are waiting to at $ 100 for long term so they can see again at 600+
early born child. Today push is simply hyped.
Sentiment: Strong Sell
It is a pure hype. SEC can suspend this stock at any day. They are not Kellog or general mills.It is just pure hype.
Look at VAPE. CBGI, CBDS, CANN, MNTR SEC cracking down hyped stocks
FBI director clarifies 'funny' marijuana comments
Jolie Lee, USA TODAY Network 4:08 p.m. EDT May 21, 2014
(Photo: Elaine Thompson, AP)
FBI Director James Comey clarified Wednesday that he has no intention of changing the bureau's current marijuana policy, which bans employing anyone known to have used pot in the past three years.
During an FBI oversight hearing, Comey said he was trying to use humor on the subject of new hires.
"I am determined not to lose my sense of humor, but unfortunately there I was trying to be both serious and funny," Comey said. "I am absolutely dead-set against using marijuana. I don't want young people to use marijuana. It's against the law."
"We have a three-year ban on marijuana. I did not say that I am going to change that ban," he added.
Earlier, the FBI acknowledged the widening acceptance of marijuana as a challenge to the agency's recruitment efforts — particularly in attracting top computer programmers and hackers for its cybersecurity efforts.
"I have to hire a great workforce to compete with those cybercriminals and some of those kids want to smoke weed on the way to the interview," Comey said during a conference Monday in New York City, reported TheWall Street Journal.
The FBI has the authority to hire 2,000 employees this year, many of them assigned to cybertasks, according to the Journal.
go and find out SEC regulations-----------------no one in M/j field making money only pure hype.Mentor has exposure 100% they will go chapter 11
As experience and knowledge about a device increase, the original classification of a device can be changed through reclassification. Two reclassification processes for medical devices described in the Food Drug and Cosmetic Act (FD&C Act) are explained below.
Reclassification Process Described in Section 513(e) of the FD&C Act
Under section 513(e) of the FD&C Act, the FDA may, on its own initiative or in response to a petition from an interested person, reclassify a device type based on “new information.” The new information received about a device must be publicly available “valid scientific evidence,” as defined in section 513(a)(3) of the FD&C Act and 21 CFR 860.7(c)(2).
If the FDA or a petitioner proposes that the device type be reclassified into a lower class (from Class III to Class II, Class II to Class I, or Class III to Class I), the FDA or the petitioner must identify sufficient valid scientific evidence to support a determination by the FDA that the safety and effectiveness of that device type can be assured through the less stringent regulatory controls of the lower class.
On July 9, 2012, the Food and Drug Administration Safety and Innovation Act (FDASIA) was enacted, changing the reclassification process from rulemaking to an administrative order process. To reclassify a device under section 513(e) of the FD&C Act, the FDA must do the following before making the reclassification final:
Publish a proposed order in the Federal Register which includes the proposed reclassification and a summary of the valid scientific evidence that supports the reclassification,
Convene a device classification panel meeting, either before or after the proposed order has published, and
Consider comments from the relevant public docket.
If the FDA is proposing to reclassify the device from Class II to Class III, the available scientific evidence must show that general controls and special controls together are not sufficient to provide a reasonable assurance of safety and effectiveness of the device. If, on the other hand, the FDA is proposing to reclassify the device from Class III to Class II, the available scientific evidence must show that general controls and special controls are sufficient to provide a reasonable assurance of safety and effectiveness of the device. Finally, if the FDA is proposing to reclassify a device from either Class III or Class II to Class I, the available scientific evidence must show that general controls would provide a reasonable assurance of safety and effectiveness of the device.
Reclassification Process Described in Section 513(f)(3) of the FD&C Act
Devices that were not available on the market before the enactment of the Medical Device Amendments to the FD&C Act, on May 28, 1976 (generally referred to as postamendments devices), are automatically classified into Class III without any FDA rulemaking process, regardless of the risks they pose.
BioElectronics Corp. A Sub-Penny Opportunity in Health Care Industry Analyst Report